Dr. James J. Mule is Associate Center Director for Translational Research & Technology Development and the U.S. Senator Connie Mack & Family Distinguished Chair, Melanoma Research and Treatment, at the H. Lee Moffitt Comprehensive Cancer Center & Hospital. He was the Director of the Tumor Immunology and Immunotherapy Clinical Research Program at the University of Michigan Comprehensive Cancer Center. Dr. Mule was also the Maude T. Lane Endowed Professor of Surgery, Department of Surgery and held the appointment of Professor in the Department of Internal Medicine. He is recognized for his translational research studies in cancer immunotherapy. His research group is involved in vaccine strategies and other approaches to stimulate the immune system to recognize and destroy tumors. The work in these areas has helped to develop new treatments for advanced cancer patients. Dr. Mule serves on the advisory boards of nine NCI-designated Comprehensive Cancer Centers and is a member of the National Cancer Institute’s Board of Scientific Counselors; he is also a member of the Center for Biologics Evaluation and Review, Food and Drug Administration’s External Board of Advisers. Dr. Mule has published nearly 200 articles in the areas of cancer vaccines and cancer immunotherapy.